Myeloproliferative Neoplasms (MPN)
Non-Transplant Therapies for Marrow Failure, AAMDSIF 2026 International Bone Marrow Failure Scientific Symposium
Urge Your U.S. Senators to Support the Bipartisan Letter to Increase Medical Research Accounts in the DoD
MPN-FIT: a randomized controlled pilot trial of supervised exercise in myeloproliferative neoplasms
Expert Opinion on the Diagnosis and Treatment of Hematologic Malignancies During Pregnancy
Abstract The diagnosis and treatment of hematologic malignancies has undergone significant advancements over the past few decades, resulting in enhanced outcomes. For hematologic malignancies diagnosed during pregnancy, this poses new questions. As possibilities continue to…
A 2026 update on myelodysplastic neoplasms: current state, challenges and future directions
Abstract Myelodysplastic neoplasms, also known as myelodysplastic syndromes (MDS), are a heterogeneous group of myeloid malignancies characterized by ineffective haematopoiesis, cytopenias and a variably increased risk of progression to acute myeloid leukaemia. MDS primarily…
Furha Cossor, M-D
Furha Cossor, MD, is a board-certified oncologist and hematologist with Saint Luke's Cancer Specialists. Dr. Cossor has a special interest in multiple myeloma, leukemia, lymphoma, myelodysplastic syndrome, and myeproliferative neoplasms.
Ludovica Marando, MD
Dr. Marando is a Hematologist in Houston, Texas. Dr. Marando is a dedicated hematologist who is passionate about understanding the mechanisms that govern somatic clonal mosaicism within the hematopoietic stem cell compartment and the factors that govern progression into overt myeloid neoplasms. I do firmly believe that a better understanding of these mechanisms can lead to a shift in treatment paradigms: prevention of deadly hematological cancers.
Brion V. Randolph, MD
Dr. Brion Randolph is a medical oncologist and hematologist with 23 years of experience treating patients with cancer and blood disorders. His expertise encompasses both oncology and hematology, allowing him to provide comprehensive care for patients facing complex diagnoses. Dr. Randolph focuses on delivering personalized treatment plans for individuals dealing with various forms of cancer and blood-related conditions.
CDK4/6 inhibition mitigates chemotherapy-induced expansion of TP53-mutant clonal hematopoiesis
Therapy-related myeloid neoplasm (tMN) is a fatal consequence of exposure to cytotoxic therapy administered in the treatment of cancer. Individuals with pre-existing TP53 clonal hematopoiesis (CH) are at high risk of tMN, with avoidance of therapy being the only strategy to…
